These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 24986093

  • 1. Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro.
    Chen SZ, Pan PP, Shen LB, Xu SS, Dai DP, Geng PW, Cai J, Cai JP, Hu GX.
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):732-8. PubMed ID: 24986093
    [Abstract] [Full Text] [Related]

  • 2. Effect of glimepiride and glibenclamide on S-warfarin 7-hydroxylation by human liver microsomes, recombinant human CYP2C9.1 and CYP2C9.3.
    Iwakawa S, Miyashita K, Hashimoto Y, Kuroda T.
    Biol Pharm Bull; 2006 Sep; 29(9):1983-5. PubMed ID: 16946524
    [Abstract] [Full Text] [Related]

  • 3. Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects.
    Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim SR, Kaniwa N, Katori N, Hasegawa R, Yasuda K, Kamide K, Miyata T, Saito Y, Sawada J.
    Drug Metab Dispos; 2009 Sep; 37(9):1895-903. PubMed ID: 19541829
    [Abstract] [Full Text] [Related]

  • 4. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
    Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M.
    Diabetes Res Clin Pract; 2006 May; 72(2):148-54. PubMed ID: 16325295
    [Abstract] [Full Text] [Related]

  • 5. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.
    Shon JH, Yoon YR, Kim MJ, Kim KA, Lim YC, Liu KH, Shin DH, Lee CH, Cha IJ, Shin JG.
    Br J Clin Pharmacol; 2005 May; 59(5):552-63. PubMed ID: 15842554
    [Abstract] [Full Text] [Related]

  • 6. In vitro and in vivo drug-drug interaction of losartan and glimepiride in rats and its possible mechanism.
    Chen SZ, Pan PP, Wang SH, Luo J, Hu GX, Xu SS, Zhang L, Yu YF.
    Pharmacology; 2015 May; 95(3-4):133-8. PubMed ID: 25823852
    [Abstract] [Full Text] [Related]

  • 7. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
    He SM, Zhou ZW, Li XT, Zhou SF.
    Curr Med Chem; 2011 May; 18(5):667-713. PubMed ID: 21182487
    [Abstract] [Full Text] [Related]

  • 8. Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1).
    Yasar U, Babaoglu MO, Bozkurt A.
    Basic Clin Pharmacol Toxicol; 2008 Aug; 103(2):176-9. PubMed ID: 18816302
    [Abstract] [Full Text] [Related]

  • 9. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
    Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivistö KT.
    Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
    [Abstract] [Full Text] [Related]

  • 10. In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride.
    Dai DP, Wang SH, Geng PW, Hu GX, Cai JP.
    Basic Clin Pharmacol Toxicol; 2014 Apr; 114(4):305-10. PubMed ID: 24118918
    [Abstract] [Full Text] [Related]

  • 11. CYP2C9 genetic variants and losartan oxidation in a Turkish population.
    Babaoglu MO, Yasar U, Sandberg M, Eliasson E, Dahl ML, Kayaalp SO, Bozkurt A.
    Eur J Clin Pharmacol; 2004 Jul; 60(5):337-42. PubMed ID: 15197523
    [Abstract] [Full Text] [Related]

  • 12. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.
    Taavitsainen P, Kiukaanniemi K, Pelkonen O.
    Eur J Clin Pharmacol; 2000 May; 56(2):135-40. PubMed ID: 10877007
    [Abstract] [Full Text] [Related]

  • 13. Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.
    Varshney E, Saha N, Tandon M, Shrivastava V, Ali S.
    Eur J Drug Metab Pharmacokinet; 2013 Dec; 38(4):275-82. PubMed ID: 23446815
    [Abstract] [Full Text] [Related]

  • 14. Role of CYP2C9 polymorphism in losartan oxidation.
    Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, Eliasson E.
    Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
    [Abstract] [Full Text] [Related]

  • 15. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase.
    Sandberg M, Yasar U, Strömberg P, Höög JO, Eliasson E.
    Br J Clin Pharmacol; 2002 Oct; 54(4):423-9. PubMed ID: 12392591
    [Abstract] [Full Text] [Related]

  • 16. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients.
    Gunes A, Coskun U, Boruban C, Gunel N, Babaoglu MO, Sencan O, Bozkurt A, Rane A, Hassan M, Zengil H, Yasar U.
    Basic Clin Pharmacol Toxicol; 2006 Feb; 98(2):197-200. PubMed ID: 16445595
    [Abstract] [Full Text] [Related]

  • 17. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
    Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmöller J.
    Clin Pharmacokinet; 2005 Feb; 44(12):1209-25. PubMed ID: 16372821
    [Abstract] [Full Text] [Related]

  • 18. Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender.
    Dorado P, Beltrán LJ, Machín E, Peñas-Lledó EM, Terán E, Llerena A, CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF.
    Pharmacogenomics; 2012 Nov; 13(15):1711-7. PubMed ID: 23171336
    [Abstract] [Full Text] [Related]

  • 19. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
    Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH.
    Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
    [Abstract] [Full Text] [Related]

  • 20. Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.
    Yasar U, Sain-Guven G, Yardimci Y, Kilicarslan A, Babaoglu MO, Bozkurt A.
    Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):73-7. PubMed ID: 21332946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.